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The intricacies of eukaryotic spell-checking
Recent work suggests that the eukaryotic system responsible for repairing
DNA mismatches, and so correcting replication errors, is more complex
than was thought; its multiple components have many cellular functions.
Anyone who has tried to type a document understands
the three opportunities to do it accurately: selecting the
correct keys in the correct order, backing up to edit
mistakes as they are made, and correcting the document
after completion using spell-checking. Cells accurately
replicate their genomes in much the same way: DNA
polymerases usually select the correct deoxynucleoside
triphosphates for incorporation, occasional mistakes are
edited by proofreading exonucleases, and rare errors left
behind by the replication machinery are later corrected
by the cell's spell-checking machinery, which undertakes
post-replication DNA-mismatch repair. Interest in this
last process in human cells was greatly stimulated two
years ago by studies suggesting that inactivation of
mismatch repair may be the initial event leading to cer-
tain types of hereditary and sporadic cancers (reviewed in
[1]). Given that many of us will eventually die from some
form of cancer, it is no surprise that the pace of studies of
mismatch repair has dramatically increased since then.
This is especially highlighted by a flurry of exciting and
surprising observations in the last few months suggesting
that the mismatch-repair system is more complex than
was previously thought, and that its multiple gene
products participate in a variety of fundamentally
important DNA transactions.
The Escherichia coli model
In Escherichia coli, replication and recombination produce
mispaired and unpaired bases in DNA that are corrected
by the mismatch-repair process outlined in Figure la [2].
Newly replicated DNA is transiently undermethylated at
adenines within GATC sequences, providing the signal
that allows the repair machinery to distinguish between
strands and so to be targetted specifically to the daughter
strand that contains the error. Repair is initiated by the
binding of a multimer - perhaps a homodimer - of the
MutS protein to the mismatch. A multimer of MutL then
forms a complex with MutS, ultimately resulting in the
activation of a latent, MutH-associated endonuclease that
incises the unmodified strand at the hemimethylated
GATC site. An experimentally inserted nick in the DNA
can alleviate the requirement for MutH incision. ATP-
dependent excision of nucleotides then proceeds from the
nick to around 100 nucleotides past the mismatch, using
MutS, MutL, DNA helicase II and an exonuclease. This
repair system can operate bidirectionally - that is, the
incised GATC site can be either 3' or 5' of the mismatch.
Depending on the position of the nick relative to the-
mismatch, one of three possible E. coli exonucleases may
perform the excision. Resynthesis of DNA is catalyzed by
the DNA polymerase III holoenzyme with single-strand
DNA-binding protein as an accessory factor, and the nick
is then sealed by DNA ligase to complete the repair.
This methyl-directed mismatch-repair system corrects
mismatches and heteroduplexes containing one to four
unpaired bases, but does not efficiently correct hetero-
duplexes containing larger numbers of unpaired bases.
The MutS and MutL components also participate in
blocking recombination between genetically divergent
DNA sequences. Although the precise details of this
process are less well understood, it presumably involves
interactions of the two proteins with recombination
intermediates containing mismatches. In addition to this
general mismatch-repair system, E. coli also contains at
least two other repair systems for correcting specific
mismatched base-pairs that result from deamination of
5-methylcytosine (VSP repair) or from oxidative stress
(MutY-dependent repair).
Multiple mismatch-repair genes in eukaryotes
The general mismatch-repair system in human cells [3]
shares several features with the E. coli system. The eight
possible mismatched base-pairs are repaired with about
the same efficiency as in E. coli, and in a strand-specific
manner. Although the signal for strand-discrimination in
vivo is unknown, repair in vitro can be directed to one
strand by a nick in the DNA substrate. The system has
the capacity to be bidirectional, and excision and resyn-
thesis occurs between the nick and the mismatch, using
proteins whose identity remains to be established.
Despite these similarities, studies in yeast, mouse and
human cells have identified more than one gene in each
with homology to MutS or MutL [1], suggesting that
mismatch repair might be more complex in eukaryotes
than in prokaryotes. This has indeed turned out to be the
case, as illustrated by more than a dozen publications on
eukaryotic mismatch repair in just the last few months.
A major step towards genetically and biochemically
dissecting mismatch repair in human cells occurred in
1993. DNA from tumors of patients with a history of a
particular type of colon cancer - hereditary non-poly-
posis colorectal cancer, HNPCC - exhibited elevated
genome-wide mutation rates in short repetitive sequen-
ces called microsatellites. With this molecular biological
marker as a clue to the nature of the defect and the loca-
tion of HNPCC-susceptibility genes, mutations that
could potentially inactivate the mismatch-repair system
were quickly identified in four genes, hMlSH2, hMLH1,
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Fig. 1. Mismatch-repair pathways; see
text for description. The MutS and MutL
protein complexes are depicted as
homodimers, with the homologous
complexes in eukaryotes depicted as
heterodimers. Subunit stoichiometries
remain to be firmly established, as do
subunit compositions in eukaryotes,
which may differ in a substrate- and/or
tissue-specific manner. The downstream
protein requirements for eukaryotic
mismatch repair also remain to be
established (as indicated by question
marks), and these may differ for the
repair of different heteroduplexes. SSB,
single-strand DNA-binding protein;
RPA, replication protein A, a eukaryotic
single-strand DNA-binding protein.
hPMS1 and hPMS2; in addition, tumor cell lines with
mutations in hMSH2 and hMLH1 were found to be
defective in mismatch-repair activity.
The hMLH1, hPMS1 and hPMS2 genes are all homologs
of the bacterial MutL gene and are closely related at the
sequence level to yeast counterparts whose inactivation
yields elevated mutation rates. Mutations in these genes
are associated with HNPCC (for example, see [4] and
references therein). Recently, Li and Modrich [5] re-
stored mismatch-repair activity to an extract made from
an hlMLH1-defective tumor cell line by a protein frac-
tion they have designated hMLHot, comprised of
hMLH1 and a second protein that is likely to be hPMS2.
A role for hPMS2 in mismatch repair is also strongly
suggested by two recent publications [6,7] showing that
extracts made from cells with mutations in hPMS2 are
defective in mismatch repair. Thus, two (or more) gene
products may be required in humans to fulfill the func-
tion of one (MutL) in E. coli. Functions for hPMS1 and
the other MutL homologs that have been described
remain to be established.
The MSH2 gene is a homolog of bacterial MrtS. It
encodes a protein that, like MutS, binds in vitro selectively
to DNA containing mispaired and unpaired bases ([8]
and references therein). Mutations in hMSH2 are associ-
ated with HNPCC and are also found in sporadic tumors
(for example, see [9] and references therein). Until
recently, it seemed possible that hMSH2 might be the
functional equivalent of bacterial MutS. This simple view
now needs revision on the basis of new information from
the cloning, sequencing and characterization of another
gene and its product. This new gene has been designated
as p160 [10] or GTBP [11,12], the latter for G-T mis-
match-binding protein, the property by which the gene
product was first identified in 1988. The 160 kDa GTBP
protein co-purifies with hMSH2 as a heterodimer, which
Drummond et al. [10] have designated hMutSot. Both
proteins are required for mismatch binding [11], and the
heterodimer is capable of restoring mismatch-repair
activity to the hMSH2-defective LoVo colon tumor cell
line [10]. Thus, more than one human gene product
fulfills the function performed by MutS in E. coli.
The situation is still more interesting, however. Extracts
of GTBP-mutant cell lines [12] do not repair substrates
containing mispaired or single unpaired bases, but do
repair those with two to five unpaired bases [10,13],
albeit with reduced efficiency [10]. These data suggest
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that, in addition to hMutSao for the correction of
mismatches and single unpaired bases, human cells may
contain one or more additional heteroduplex DNA-
binding protein complexes for the repair of larger non-
homologous regions (Fig. c). What might the protein(s)
be? Extracts of hMSH2-mutant LoVo cells are repair-
deficient for all substrates examined to date [10,13], sug-
gesting that hMSH2 is involved in repairing a wide
variety of substrates. Another possibility is suggested by a
recent study by Strand et al. [14] demonstrating that a
yeast strain with a mutation in MSH3, another MutS
homolog, has an elevated mutation rate for dinucleotide
repeats but not for non-repetitive sequences. This implies
that the cells have a repair defect for substrates contain-
ing two unpaired bases but not for those with mis-
matches, the reciprocal specificity to that of a GTBP
mutation in human cells. Thus, a logical candidate pro-
tein to replace the question mark alongside hMSH2 in
the top of Figure c would be the human homolog of
yeast MSH3. Strand et al. [14] also discuss the interesting
possibility that there may be mismatch-repair complexes
that are specific for the correction of leading- and
lagging-strand replication errors.
Although about half of the HNPCC families examined
to date have mutations in hMSH2, the situation is very
different for the gene encoding its partner in the hMutSao
complex, GTBP. Papadopoulos et al. [12] failed to detect
GTBP mutations in any of 20 HNPCC families that have
yet to be assigned a genetic defect. These unassigned
families could obviously have mutations in mismatch-
repair genes encoding an exonuclease (for example, see
[15]), helicase or DNA polymerase (for example, see
[16]), or in genes involved in other DNA transactions
which, when mutant, lead to elevated mutation rates.
But the new studies offer another possibility. The
hypothesis that an elevated mutation rate is required in
order to obtain the multiple mutations needed for tumor
development [17] is consistent with the greatly elevated
mutation rates observed in hMSH2- and hMLH1-
defective tumor cell lines - but GTBP-defective cells,
which retain some capacity to repair substrates with two
or more unpaired bases, have more highly elevated muta-
tion rates in non-repetitive and homopolymeric
sequences than in dinucleotide repeats ([12] and refer-
ences therein). Taken together, these findings imply that
a candidate gene whose defect might lead to tumor for-
mation in HNPCC patients would encode a protein
required for the repair of substrates with two or more
unpaired bases. This protein could conceivably be part of
a second hMutS or hMutL complex involving one or
more of the other MutS/MutL homologs that as yet have
no known functions. The new data are also consistent
with the possibility that the risk posed to downstream
genes which, if altered, could contribute to tumor pro-
gression (for example, the type II TGF[ receptor gene;
see [18]) is proportional to the amount of functionally
important repetitive sequences they contain. Might this
be part of the explanation for the tissue-specificity of
HNPCC-associated tumors?
These musings certainly do not deny the potential
involvement of GTBP mutations in cancer, as one of the
GTBP-mutant cell lines described by Papadopoulos et al.
[12] was derived from a colon tumor, and some tumors
have been suggested to manifest a low degree of
microsatellite instability. The new data on GTBP-mutant
cell lines also have implications for the use of microsatel-
lite instability as a molecular marker of tumor cells. Thus,
the absence of microsatellite instability need not indicate
a completely functional mismatch-repair system and the
presence of microsatellite instability does not automati-
cally imply that repair of mismatches or of unpaired bases
is defective.
Multiple functions for mismatch-repair genes
Several recent studies indicate that, as in bacteria,
eukaryotic mismatch-repair genes safeguard the genome
from promiscuous genetic exchange between DNA
strands with less than perfect homology. For example,
Selva et al. [19] recently observed strongly elevated rates of
mitotic homeologous recombination (between partially
divergent sequences) in yeast strains mutant in MSH2 and
MSH3, and de Wind et al. [20] have shown that MSH2
mutant mouse cells also have elevated rates of recombina-
tion between nonidentical DNA sequences. Interestingly, a
deletion of yPMS1 (homologous to hPMS2) had no effect
[19], suggesting that there may be specialization among the
various mismatch-repair gene products for the repair of
replication errors versus recombination intermediates.
One wonders whether GTBP or other lMutS or MutL
homologs influence homeologous recombination rates.
Baker et al. [21] have recently generated mice with a null
mutation in PMS2 and found that males are infertile.
Only abnormal spermatozoa were seen, and examination
of axial element and synaptonemal complex formation
during prophase of meiosis I indicated abnormal chro-
mosome synapsis. Thus, this mismatch repair gene is also
required for male fertility and normal chromosome
synapsis. Interestingly, mice that are homozygous for
mutations in MSH2 [20] or PMS2 [21] are viable,
although the mice do get lymphomas, and microsatellite
instability can be detected in DNA from various tissues.
Non-lethal hMLH1 and hPMS2 mutations that inactivate
mismatch repair are also found in cell lines derived from
HNPCC patients [6]. Curiously, each of these mismatch-
repair-defective cell lines is detectably mutant in only
one of the two alleles of hMLH1 or hPMS2, in contrast
to the usual situation with loss-of-function mutations
wherein both alleles are mutant and/or lost. The appar-
ent heterozygosity in these patients may thus indicate
that their mutations are 'dominant-negative', interfering
with the function of the wild-type protein produced
from the other allele - as might be anticipated for one
component of a repair pathway involving multiple inter-
acting gene products. The fact that these phenotypically
mismatch-repair-defective patients are not rife with
tumors at an early age also suggests that the mismatch-
repair defect alone is not sufficient for tumorigenesis.
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Additional roles for mismatch-repair genes are suggested
by other recent studies. Hawn et al. [22] have obtained
evidence that the mismatch-repair system may participate
in control of the cell cycle at the G2 'checkpoint' that
prevents cell-cycle progression in response to treatment
with the base analog 6-thioguanine or the DNA-
damaging agent N-methyl-N'-nitro-N-nitrosoguanidine.
The fact that mismatch-repair-defective cells are highly
resistant to alkylating agents has important clinical impli-
cations and is consistent with a role for mismatch repair
in sensing certain types of DNA damage. Conversely, the
p53 protein, known to be a key participant in cell-cycle
checkpoint control after DNA damage, has recently been
shown to bind selectively to DNA containing unpaired
nucleotides [23]. Finally, Mellon and Champe [24] have
shown that MutS and MutL are required in E. coli for
transcription-coupled nucleotide-excision repair of ultra-
violet photoproducts occurring within the DNA of the
lactose operon. If similar observations are forthcoming in
eukaryotes, this would imply that some mismatch-repair
genes may have a role in nucleotide-excision repair, a
very different type of repair process [25].
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